Meet Boehringer Ingelheim, Genentech, Apexigen & more at the 5th Cell Engager Summit 2023
The good news continues as BioAtla Announces FDA Clearance of Investigational New Drug Application for BA3182, a CAB-EpCAMxCAB-CD3 Bispecific T-Cell Engager for the Treatment of…
Read More...
Read More...